Intermittent PARP inhibitor regimen in ovarian cancer (IPIROC): A proof-of-concept exploratory pragmatic study (IPIROC#02) using generic rucaparib with pharmacodynamic assessment.

Authors: Asima Mukhopadhyay, Tanushri Ghosh, Daity Bhattacharjee, Dona Chakraborty, Sib Sankar Roy, Atanu Bhattacharjee, Roma Gupta, Papiya Mukherjee, Somoshree Sengupta, Sharmistha Das, Ranajit Mandal, Puja Chatterjee, Manisha Vernekar, Rahul Roy Chowdhury, Amlan Kanti Sarkar,

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17597

Source: Full article

---

Abstract

e17597